Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.